Page last updated: 2024-10-31

nafamostat and Allodynia

nafamostat has been researched along with Allodynia in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research Excerpts

ExcerptRelevanceReference
"The established referred allodynia/hyperalgesia following cerulein treatment was abolished by post-treatment with nafamostat mesilate, a proteinase inhibitor, and with capsazepine, a TRPV1 antagonist, in mice."3.76The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice. ( Akashi, R; Ishikura, H; Kawabata, A; Kitamura, T; Matsumura, K; Matsunami, M; Naruse, M; Nishimura, S; Sekiguchi, F; Shinozaki, Y, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nishimura, S1
Ishikura, H1
Matsunami, M1
Shinozaki, Y1
Sekiguchi, F1
Naruse, M1
Kitamura, T1
Akashi, R1
Matsumura, K1
Kawabata, A1

Other Studies

1 other study available for nafamostat and Allodynia

ArticleYear
The proteinase/proteinase-activated receptor-2/transient receptor potential vanilloid-1 cascade impacts pancreatic pain in mice.
    Life sciences, 2010, Nov-20, Volume: 87, Issue:19-22

    Topics: Acute Disease; Animals; Benzamidines; Capsaicin; Ceruletide; Disease Models, Animal; Gene Expression

2010